Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Director David P. Hochman purchased 5,000 shares of the company’s stock in a transaction on Monday, November 13th. The shares were purchased at an average price of $6.90 per share, with a total value of $34,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) traded down $0.40 during midday trading on Tuesday, hitting $6.85. The stock had a trading volume of 883,300 shares, compared to its average volume of 811,852. Corbus Pharmaceuticals Holdings, Inc. has a 52 week low of $5.30 and a 52 week high of $10.50.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals Holdings had a negative return on equity of 96.02% and a negative net margin of 1,040.41%. The company had revenue of $0.80 million during the quarter. research analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -0.63 EPS for the current fiscal year.
Several equities research analysts have commented on the company. Cantor Fitzgerald set a $24.00 price target on Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a research note on Wednesday, August 9th. BidaskClub lowered Corbus Pharmaceuticals Holdings from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. ValuEngine lowered Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th. Finally, Noble Financial restated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $20.75.
Corbus Pharmaceuticals Holdings Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.